Exosomes derived from Rab27a‑overexpressing tumor cells elicit efficient induction of antitumor immunity

Li,Wenhai; Mu,Deguang; Tian,Feng; Hu,Yunsheng; Jiang,Tao; Han,Yong; Chen,Jiakuan; Han,Guoliang; Li,Xiaofei

doi:10.3892/mmr.2013.1738

Exosomes derived from Rab27a‑overexpressing tumor cells elicit efficient induction of antitumor immunity

Authors:
- Wenhai Li
- Deguang Mu
- Feng Tian
- Yunsheng Hu
- Tao Jiang
- Yong Han
- Jiakuan Chen
- Guoliang Han
- Xiaofei Li
View Affiliations

Affiliations: Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Department of Respiratory Medicine, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Department of Orthopaedic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: October 18, 2013 https://doi.org/10.3892/mmr.2013.1738
Pages: 1876-1882

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of mortality worldwide. However, there is a lack of effective therapeutic strategies. Currently, tumor immunotherapy based on exosomes, which are secreted by a variety of cell types including tumor cells, has drawn particular attention and are suggested to have the potential for exploitation in tumor therapy. Nevertheless, the therapeutic efficacy mediated via tumor cell‑derived exosomes is not satisfactory. Rab27a, one of the Rab family of small GTPases, has been suggested to be important in exosome secretion. Thus, the purpose of the present study was to examine whether exosomes derived from Rab27a‑overexpressing cells elicited more potent antitumor immunity. A Rab27a‑overexpressing line was established via transfection of a Rab27a overexpression vector into the human non‑small‑cell lung cancer cell line, A549. Exosomes were isolated and the typical exosomal protein markers, CD9, CD63, heat shock protein (Hsp) 70 and Hsp90, were found to be enriched in the exosomes derived from Rab27a‑overexpressing cells. Subsequently, these exosomes were demonstrated to be capable of upregulating major histocompatibility complex class II molecules as well as the co‑stimulatory molecules CD80 and CD86 on dendritic cells (DCs), suggesting that more potent maturation of DCs was induced. Furthermore, DCs loaded with exosomes derived from Rab27‑overexpressing cells significantly promoted CD4+ T cell proliferation in vitro. In addition, in vivo immunization of exosomes derived from Rab27a‑overexpressing cells inhibited tumor growth in a mouse model. It was also demonstrated that splenocytes from mice immunized with exosomes derived from Rab27‑overexpressing cells expressed high levels of type I cytokines, including IL‑2 and IFN‑γ, which are important in the regulation of cell‑mediated antitumor immunity. Collectively, it was demonstrated that exosomes derived from Rab27a‑overexpressing cancer cells elicited more potent antitumor immune effects, which may provide novel insights for the development of efficient exosome‑based cancer vaccines.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
2	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
3	Thomas L: On immunosurveillance in human cancer. Yale J Biol Med. 55:329–333. 1982.PubMed/NCBI
4	Kaplan DH, Shankaran V, Dighe AS, et al: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 95:7556–7561. 1998. View Article : Google Scholar : PubMed/NCBI
5	Shankaran V, Ikeda H, Bruce AT, et al: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107–1111. 2001. View Article : Google Scholar : PubMed/NCBI
6	Wolfers J, Lozier A, Raposo G, et al: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 7:297–303. 2001.PubMed/NCBI
7	Navabi H, Croston D, Hobot J, et al: Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis. 35:149–152. 2005. View Article : Google Scholar : PubMed/NCBI
8	Pan BT and Johnstone RM: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33:967–978. 1983. View Article : Google Scholar : PubMed/NCBI
9	Harding C, Heuser J and Stahl P: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 97:329–339. 1983. View Article : Google Scholar : PubMed/NCBI
10	Pan BT, Teng K, Wu C, Adam M and Johnstone RM: Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol. 101:942–948. 1985. View Article : Google Scholar : PubMed/NCBI
11	Yang C and Robbins PD: The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol. 2011:8428492011. View Article : Google Scholar : PubMed/NCBI
12	Stoorvogel W, Kleijmeer MJ, Geuze HJ and Raposo G: The biogenesis and functions of exosomes. Traffic. 3:321–330. 2002. View Article : Google Scholar : PubMed/NCBI
13	Mignot G, Roux S, Thery C, Ségura E and Zitvogel L: Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med. 10:376–388. 2006. View Article : Google Scholar : PubMed/NCBI
14	Valadi H, Ekström K, Bossios A, et al: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
15	Subra C, Laulagnier K, Perret B and Record M: Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie. 89:205–212. 2007. View Article : Google Scholar : PubMed/NCBI
16	Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A and Ratajczak MZ: Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 20:1487–1495. 2006. View Article : Google Scholar : PubMed/NCBI
17	Zitvogel L, Regnault A, Lozier A, et al: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 4:594–600. 1998. View Article : Google Scholar : PubMed/NCBI
18	Raposo G, Nijman HW, Stoorvogel W, et al: B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 183:1161–1172. 1996. View Article : Google Scholar : PubMed/NCBI
19	Ostrowski M, Carmo NB, Krumeich S, et al: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 12:19–30, sup pp. 11–13. 2010. View Article : Google Scholar : PubMed/NCBI
20	Zerial M and McBride H: Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 2:107–117. 2001. View Article : Google Scholar : PubMed/NCBI
21	Johnson JL, Brzezinska AA, Tolmachova T, et al: Rab27a and Rab27b regulate neutrophil azurophilic granule exocytosis and NADPH oxidase activity by independent mechanisms. Traffic. 11:533–547. 2010. View Article : Google Scholar : PubMed/NCBI
22	Griscelli C, Durandy A, Guy-Grand D, et al: A syndrome associating partial albinism and immunodeficiency. Am J Med. 65:691–702. 1978. View Article : Google Scholar : PubMed/NCBI
23	Klein C, Philippe N, Le Deist F, et al: Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr. 125:886–895. 1994. View Article : Google Scholar : PubMed/NCBI
24	Munafó DB, Johnson JL, Ellis BA, et al: Rab27a is a key component of the secretory machinery of azurophilic granules in granulocytes. Biochem J. 402:229–239. 2007.PubMed/NCBI
25	Guo J, Wang B, Zhang M, et al: Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther. 9:793–803. 2002. View Article : Google Scholar
26	Chaput N, Taïeb J, Schartz NE, et al: Exosome-based immunotherapy. Cancer Immunol Immunother. 53:234–239. 2004. View Article : Google Scholar
27	Chen W, Wang J, Shao C, et al: Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol. 36:1598–1607. 2006. View Article : Google Scholar : PubMed/NCBI
28	Lv LH, Wan YL, Lin Y, et al: Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem. 287:15874–15885. 2012. View Article : Google Scholar
29	Desnos C, Schonn JS, Huet S, et al: Rab27A and its effector MyRIP link secretory granules to F-actin and control their motion towards release sites. J Cell Biol. 163:559–570. 2003. View Article : Google Scholar : PubMed/NCBI
30	Stinchcombe JC, Barral DC, Mules EH, et al: Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J Cell Biol. 152:825–834. 2001. View Article : Google Scholar : PubMed/NCBI
31	Barral DC, Ramalho JS, Anders R, et al: Functional redundancy of Rab27 proteins and the pathogenesis of Griscelli syndrome. J Clin Invest. 110:247–257. 2002. View Article : Google Scholar : PubMed/NCBI
32	Bobrie A, Krumeich S, Reyal F, et al: Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 72:4920–4930. 2012. View Article : Google Scholar : PubMed/NCBI
33	Peinado H, Alečković M, Lavotshkin S, et al: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18:883–891. 2012. View Article : Google Scholar : PubMed/NCBI
34	Cho BK, Palliser D, Guillen E, et al: A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity. 12:263–272. 2000. View Article : Google Scholar : PubMed/NCBI
35	Fowler DW, Copier J, Wilson N, Dalgleish AG and Bodman-Smith MD: Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother. 61:535–547. 2012.
36	Tan A, De La Peña H and Seifalian AM: The application of exosomes as a nanoscale cancer vaccine. Int J Nanomedicine. 5:889–900. 2010.PubMed/NCBI
37	Morse MA, Garst J, Osada T, et al: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 3:92005. View Article : Google Scholar : PubMed/NCBI
38	Dai S, Wei D, Wu Z, et al: Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther. 16:782–790. 2008. View Article : Google Scholar : PubMed/NCBI
39	Guo F, Chang CK, Fan HH, et al: Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid. J Int Med Res. 36:1342–1353. 2008. View Article : Google Scholar : PubMed/NCBI
40	Hao S, Ye Z, Yang J, Bai O and Xiang J: Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity. Cancer Biother Radiopharm. 21:146–154. 2006. View Article : Google Scholar : PubMed/NCBI
41	Hao S, Bai O, Yuan J, Qureshi M and Xiang J: Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol. 3:205–211. 2006.